Signal
Akeso’s ivonescimab marks a milestone for Chinese biotech at ASCO 2026
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-06-03 13:04 UTCUpdated 2026-06-03 13:04 UTC
rss
clinical_trialsdrug_developmentbiotech_fundingr_and_d
Trend in the last 24h
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
In 2017, Nanjing Legend Biotech unexpectedly captured global attention at ASCO with Carvykti, a cell therapy showing a 100% objective response rate, effectively putting Chinese biotech on the world map. Building on this momentum, Akeso took center stage at ASCO 2026 when its drug ivonescimab became the first Chinese data set to be featured in a plenary session, underscoring China’s rising influence and competitiveness in global biotech innovation and clinical research.
Entities
Nanjing Legend BiotechAkesoCarvyktiivonescimab
Score total
0.7
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
50%
Why now
- ASCO 2026 plenary session featured the first-ever Chinese dataset, marking a historic moment.
- Nearly a decade after the breakthrough with Carvykti, Chinese biotech continues to advance.
- Reflects ongoing momentum and maturation of China’s biotech industry on the world stage.
Why it matters
- Demonstrates China’s growing influence in global biotech innovation and clinical research.
- Highlights successful Chinese biotech products gaining international validation.
- Signals increasing competitiveness of Chinese biotech in global drug development and funding.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Nanjing Legend Biotech’s Carvykti achieved a 100% objective response rate at ASCO 2017, putting Chinese biotech on the global map.
- Akeso’s ivonescimab was the first Chinese data set to be featured in a plenary session at ASCO 2026.
How sources frame it
- Fierce Biotech: neutral
This narrative highlights key milestones in Chinese biotech's rise at ASCO, emphasizing clinical trial success and international recognition.
All evidence
All evidence
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy tha...
Fierce Biotech · fiercebiotech.com · 2026-06-03 13:04 UTC
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy tha...
Fierce Pharma (All) · fiercepharma.com · 2026-06-03 13:04 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (1)
- Fierce Pharma (All) (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- fiercepharma.com (1)